Generation Bio Co.

Generation Bio Co.

Generation Bio Co.

Overview
Headquarters

301 Binney Street, Cambridge, MA, 02142, USA

Type of Company

Public

Employees (Worldwide)

100

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology
Wholesale: Consumer Non-Durables/Sundries

Company Description

Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Executives & Employees

Founder

Founder

President & Chief Executive Officer

Chief Financial & Accounting Officer

Chief Development Officer

Chief Scientific Officer

Chief Medical Officer

Chief Legal Officer

Chief Business Officer

Vice President, Head of Gene Therapy

Board of Directors

Co-Founder at Disarm Therapeutics, Inc.

Former Director of Finance at Bristol-Myers Squibb Company

Chief Development Officer at Obsidian Therapeutics, Inc.

Director, President & Chief Executive Officer at Albireo Pharma, Inc.

Chief Executive Officer at Nimbus Apollo, Inc.

President & Chief Executive Officer at Aeglea BioTherapeutics, Inc.

Chief Innovation Officer at SAGE Therapeutics, Inc.

President & Chief Executive Officer at Generation Bio Co.

Paths to Generation Bio Co.
Potential Connections via
Relationship Science
You
Generation Bio Co.
Owners & Shareholders
Details Hidden

FCM seeks investments across asset classes and around the world through a process of bottom-up fundamental research and analysis emphasizing capital preservation. Their investment strategies include Credit Investments, Long/Short Equity, Merger Arbitrage, Risk Arbitrage, Real Estate Investments and Direct Investments. Investment ideas compete for capital based on in-depth, critical assessment of specific risks and rewards. Risk is monitored and managed through rigorous and thorough analysis of each investment and, at the portfolio level, through risk management analytics and overlay and tail-risk hedging.

Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm’s in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech’s investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Recent Transactions
Details Hidden

Generation Bio Co. issued USD Common Stock

Details Hidden

Generation Bio Co. issued USD Common Stock

Details Hidden

Generation Bio Co. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onGeneration Bio Co. issued USD Common Stock

Underwriter

Advised onGeneration Bio Co. issued USD Common Stock

Underwriter

Advised onGeneration Bio Co. issued USD Common Stock

Attorney

Advised onGeneration Bio Co. issued USD Common Stock

Legal Advisor

Advised onGeneration Bio Co. issued USD Common Stock

Advisors & Consultants
Consultant

Chief Financial Officer at Ribon Therapeutics, Inc.

Key Stats and Financials As of 2020
Market Capitalization
$1.62B
Total Enterprise Value
$510M
Earnings Per Share
$-2.95
Revenue
$0
Net Profit
$-80.5M
EBITDA
$-77.7M
Total Debt
$0
Total Equity
$268M
TEVNet Income
-6.34x
Debt TEV
0x
Investors
Details Hidden

The Invus Group originates, structures and acts as a lead equity investor in a variety of private equity situations including buy-outs, early-stage venture capital and expansion financings. The firm makes investments in a range of industries including consumer products and services, food, specialty retailing, software, telecommunications, medical devices, biotechnology and business products and services.The Invus Group makes majority control investments in private, high-growth companies. The firm also makes minority investments in high-growth companies where they can add strategic value through partnership with the owners and managers. In addition, the Invus Group takes long-term positions in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Most of their investments are in companies located in the US and Europe.

Details Hidden

SVB Financial Group provides diversified financial services to emerging, growth and established technology companies and the life science, cleantech, venture capital, private equity and premium wine markets. Through its focus on specialized markets and extensive knowledge of the people and business issues driving them, SVB Financial Group provides a level of service and partnership that measurably impacts its clients' success. Headquartered in Santa Clara, Calif., the company offers its clients commercial, investment, merchant and private banking, as well as value-added services using its knowledge and networks. Founded in 1983, SVB Financial Group serves clients around the world through 26 domestic offices, and international subsidiaries in the U.K., Israel, India and China, and an extensive network of relationships with venture capitalists worldwide. With solid understanding of the true risks and rewards faced by companies in dynamic markets, the company is widely recognized for its ability to develop innovative approaches to meet the unique financial needs of its clients. SVB Financial Group began serving the technology and life science markets at a time when they were not well-understood by the financial services industry and when many of the leading companies in these industries were just getting started. At that time, many of these companies had yet to show profits and were not considered creditworthy by local community or regional banks. Over nearly three decades, SVB Financial Group has become one of the most respected names in the financial services industry. The company has created innovative solutions for some of the world's most successful technology and life sciences companies. These companies face unique challenges and require special services, such as finding the right venture capitalist or angel investor, securing capital to support rapid growth, or driving overseas expansion. SVB Financial Group offers products and services specifically tailored to meet our clients' needs at every stage of corporate growth. SVB Financial Group's businesses include Silicon Valley Bank, SVB Capital, SVB Analytics and SVB Private Bank. Today, SVB Financial Group has more than 1,400 employees and $19.4 billion in total assets. The company operates offices throughout Silicon Valley in Santa Clara, Menlo Park — the center of California's venture capital community, Palo Alto and Pleasanton. Other regional offices within California include Irvine, San Diego, San Francisco, Santa Rosa, St. Helena, and Sherman Oaks. Across the country, SVB Financial Group operates in Atlanta, Georgia; Austin, Texas; Beaverton, Oregon; Broomfield, Colorado; Chicago, Illinois; Dallas, Texas; Minnetonka, Minnesota; Morrisville, North Carolina; New York, New York; Newton, Massachusetts; Radnor, Pennsylvania; Salt Lake City, Utah; Seattle, Washington; Tempe, Arizona; and Vienna, Virginia. International subsidiaries are located in Bangalore, India; Mumbai, India; Herzliya Pituach, Israel; Beijing, China, Shanghai, China; and London, United Kingdom

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Generation Bio Co.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Generation Bio Co.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Generation Bio Co..